Shares of Exact Sciences Are Skyrocketing - Can This Trend Continue?

Exact Sciences stock is trading -25.2% below its average target price of $92.82 after marking a 7.5% during today's evening session. Analysts are giving the mid-cap Medical Specialities company an average rating of buy and target prices ranging from $66.0 to $120.0 per share.

Exact Sciences's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 4.1%. The stock's short ratio is 4.68. The company's insiders own 0.94% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.

Another number to watch is the company's rate of institutional share ownership, which now stands at 90.7%. In conclusion, we believe there is mixed market sentiment regarding Exact Sciences.

Institutions Invested in Exact Sciences

Date Reported Holder Percentage Shares Value
2023-09-30 JP Morgan Chase & Company 10% 18,292,619 $1,270,056,542
2023-09-30 Vanguard Group Inc 10% 17,444,693 $1,211,185,040
2023-09-30 Blackrock Inc. 6% 11,575,558 $803,690,995
2023-09-30 Wellington Management Group, LLP 6% 10,820,873 $751,293,215
2023-09-30 Capital World Investors 4% 6,928,647 $481,055,963
2023-09-30 ARK Investment Management, LLC 3% 6,280,931 $436,085,041
2023-09-30 State Street Corporation 2% 4,510,603 $313,171,167
2023-09-30 Baillie Gifford and Company 2% 4,066,330 $282,325,293
2023-09-30 Artisan Partners Limited Partnership 2% 3,961,514 $275,047,918
2023-09-30 Ameriprise Financial, Inc. 2% 3,239,648 $224,928,761
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.